Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. - Wikidata - awgldk - TriplyDB

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

http://www.wikidata.org/entity/Q34424907

about

Inflammation and insulin resistance Pioglitazone for adults with high risk of developing type 2 diabetes mellitus Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors The metabolic consequences of sleep deprivation Prevention of type 2 diabetes among women with prior gestational diabetes mellitus Treatment of prediabetes Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus Type 2 diabetes after gestational diabetes: The influence of changing diagnostic criteria Prevention of type 2 diabetes mellitus in women with previous gestational diabetes mellitus The current role of thiazolidinediones in diabetes management.The management of type 2 diabetic patients with hypoglycaemic agents Are thiazolidinediones good or bad for the heart?Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure.Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span Insulin resistance as estimated by the homeostatic method at diagnosis of gestational diabetes: estimation of disease severity and therapeutic needs in a population-based study.Actos Now for the prevention of diabetes (ACT NOW) study.An islet in distress: β cell failure in type 2 diabetes.Translating an evidence-based lifestyle intervention program into primary care: lessons learned.Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein.Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy Managing women with gestational diabetes mellitus in the postnatal period.Longitudinal changes in insulin sensitivity and beta cell function between women with and without a history of gestational diabetes mellitus HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings Weight considerations in pharmacotherapy for type 2 diabetes Pharmacogenetics of Anti-Diabetes Drugs.Preterm birth and subsequent risk of type 2 diabetes in black women Defining and achieving treatment success in patients with type 2 diabetes mellitus Role of sleep duration in the regulation of glucose metabolism and appetite.Body and liver fat mass rather than muscle mitochondrial function determine glucose metabolism in women with a history of gestational diabetes mellitus.Healthful dietary patterns and type 2 diabetes mellitus risk among women with a history of gestational diabetes mellitus.Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.What is type 2 diabetes?Chronically increased S6K1 is associated with impaired IRS1 signaling in skeletal muscle of GDM women with impaired glucose tolerance postpartum Inherited destiny? Genetics and gestational diabetes mellitus.Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.Variation in IGF2BP2 interacts with adiposity to alter insulin sensitivity in Mexican Americans

P2860

Q22241893-6091E3E1-95D3-46AB-BF6E-C1417B9A0AED Q24187448-6CD25533-D80A-4F9C-8EB9-55D2DF4142BE Q24195168-07AEC6BC-56A6-48D2-8AEA-0795529FCD05 Q24202245-C8CA5758-FD47-4D89-9CC2-88B50E3852A0 Q24598747-86C446FB-DDD9-4FDF-AC26-0BA66C024865 Q24681664-B1BF3909-72A7-45A2-8C1E-F30831EE64FE Q26782491-712590FA-1B9C-4672-AE05-EBC6D73ACE7E Q26783350-685403B5-3E7E-44CA-809C-8B22094C6000 Q26830871-D0D23DAA-089C-4B92-8BFA-03C8B670992F Q26864403-CB22B4BB-29C8-42E6-AD55-10D733B733DE Q28084288-F08D220E-5B88-44F4-9B09-9E53BFBA3367 Q28359716-663188CE-AECA-4119-9D32-A6F8B3FCD41C Q30250347-4FB64760-2CB7-4E52-A4CF-2121CC1F9346 Q30417363-FB5AA353-87C2-4710-A7BE-4D23B6FB89ED Q30435005-5EF4374B-C43A-418B-93DE-7F9195B0E23E Q30438373-FFEB8FD0-232C-474E-A75D-4AACE4733BA9 Q30572405-DE4DB171-1570-48B3-AF8B-F4EDAA6F9879 Q31122472-F873FE48-862D-4BB6-A926-6636A74BC2CD Q33488336-2A18C66E-415F-4531-A2C4-465F0D7E552B Q33558360-E1CAD578-4B70-40C1-9245-196A9420DDA2 Q33571539-F344EEBC-4D38-44FA-A344-CCB0B8653679 Q33602322-C76F3D38-6F26-4D89-A891-178CF0CD651F Q33610749-9BA94A6C-E727-4A79-A3B6-DFD5225AEBBE Q34069687-3E991BFB-1B02-4288-81F1-3E88AC0948AE Q34069891-1BCA0EE5-766C-401A-B232-9F109031385F Q34069926-A2275A32-DC68-46B7-9A86-5FA28C2AFB07 Q34159414-A93727B8-629D-4EA7-BA1D-F41C4E6389D0 Q34181995-AAC1BBE7-3569-4DF4-91C1-83F633C491B2 Q34270460-C740ECD6-E692-4ABD-B060-9EF26D36F159 Q34374314-3E2555DC-59BA-4060-9C46-974BBB98BAB9 Q34479944-D3BFFAF6-2D06-4BA8-8746-B8515E64E174 Q34507228-FD9C0F3C-ECAD-4F1A-8EA3-3F3E9DBEB33D Q34642708-7F7076E3-CC6B-4ED4-9C7E-11F6449B68CF Q34750027-D56A38DF-A446-41D0-A517-ED25D0AABF73 Q34777344-25BAF2BD-CF29-4E4A-AB62-C530E099847C Q34894537-BA1505EB-4C8C-43CC-AB5F-6E6BC9E15F8E Q34971477-00CD4993-BDC5-49ED-85A7-6992938B35F7 Q35034772-ABC568AB-5E6B-40F3-9A8A-6E110089B973 Q35090416-45657F24-03D4-4C4C-A400-E72246B3876D Q35170934-AD8D3AC5-7E5B-4723-8A31-101B87F196B0

P2860

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

http://www.wikidata.org/entity/Q34424907

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@ast

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@en

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@nl

type

label

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@ast

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@en

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@nl

prefLabel

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@ast

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@en

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@nl

P1433

Q34424907-CB91D8F0-0A33-4042-9313-CA82BDEF9164

P1476

Q34424907-32B300ED-BA15-4C4F-9592-47D1556DC410

P2093

Q34424907-021EA270-4EFE-4706-AB9B-22BD4242A061

Q34424907-11ED8A1B-0858-4E0E-8987-59490C235142

Q34424907-60E20713-EBB5-4577-AEA4-6D77DCD7EC52

Q34424907-6FDA6C50-C344-4126-AE30-52C5A7C2810B

Q34424907-9FF66168-F80E-431E-948F-FF1A4F33DE4D

Q34424907-A3E8800E-12A4-4FB5-931A-2FC8E2F79878

Q34424907-D5A19DDF-5477-498C-BB63-DDE05A9B7934

Q34424907-FA5C1F10-5444-4E2A-9B4E-93DED59ED52B

P2860

Q34424907-00435FBE-FA5D-4CD4-85AB-48FDC9F64FC2

Q34424907-17425108-61CC-4794-AA15-61C8364C64F2

Q34424907-2AD3BA4D-CDA0-4290-96F3-B4C4F4EAE04F

Q34424907-32CD123B-26B4-4831-9DC4-A8EA814B2782

Q34424907-35CB8F22-EF90-4AD2-929D-1113ECBFDF78

Q34424907-3C7FD268-358F-4B75-9B39-A069198CBEF6

Q34424907-43729C3D-987C-49B7-902B-4497149B79EB

Q34424907-4E9F0518-2504-4121-A948-083B45D3E67F

Q34424907-573051A5-82B4-4992-A294-0831CB3CC879

Q34424907-74BF2A22-C6CA-4CE5-9095-50B6DEEB2BA2

P304

Q34424907-2A79B50B-F784-4040-8671-20AB8B467F81

P31

Q34424907-AB6F295E-6CD0-4051-9BF6-1632ED515D95

P356

Q34424907-307B82D4-CBA8-48BB-9597-9DFE91F2FC2B

P407

Q34424907-B48B6418-92A3-4F08-8500-6262F9267FE2

P433

Q34424907-09E6D296-45F4-4D35-B81F-838DDFD7BD24

P478

Q34424907-0238DC8A-1189-48F8-89D9-A6B22F166F1D

P577

Q34424907-2F33B105-3763-4C93-9C60-7216A485DB29

P5875

Q34424907-A17991AD-4E06-49B8-9431-39CE8DB157B3

P698

Q34424907-7EC10263-AD23-4BEC-91FF-B4A1D07076AC

P921

Q34424907-436AA027-FBA5-4C8A-B2C3-15DEA46704D9

P932

Q34424907-C6E5D6DE-F081-48F2-976A-9C9FFC85ADDD

P356

DIABETES.55.02.06.DB05-1066

P1433

P1476

Effect of pioglitazone on panc ...... th prior gestational diabetes.

@en

P2093

Anny H Xiang

http://www.w3.org/2001/XMLSchema#string

Aura Marroquin

http://www.w3.org/2001/XMLSchema#string

Cesar Ochoa

http://www.w3.org/2001/XMLSchema#string

Jose Goico

http://www.w3.org/2001/XMLSchema#string

Miwa Kawakubo

http://www.w3.org/2001/XMLSchema#string

Ruth K Peters

http://www.w3.org/2001/XMLSchema#string

Siri L Kjos

http://www.w3.org/2001/XMLSchema#string

Thomas A Buchanan

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Gestational diabetes mellitus.

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease.

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

The defective glucose sensitivity of the B cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia.

Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig.

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.

P304

517-522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIABETES.55.02.06.DB05-1066

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7329617

http://www.w3.org/2001/XMLSchema#string

P698

16443789

http://www.w3.org/2001/XMLSchema#string

P921

gestational diabetes

P932

1389697

http://www.w3.org/2001/XMLSchema#string